Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 3:10:1196966.
doi: 10.3389/fmed.2023.1196966. eCollection 2023.

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis)

Luigi Gargiulo  1   2 , Luciano Ibba  1   2 , Piergiorgio Malagoli  3 , Fabrizio Amoruso  4 , Giuseppe Argenziano  5 , Anna Balato  5 , Federico Bardazzi  6 , Martina Burlando  7 , Carlo Giovanni Carrera  8 , Giovanni Damiani  9 , Paolo Dapavo  10 , Valentina Dini  11 , Gabriella Fabbrocini  12 , Chiara Franchi  9 , Francesca Maria Gaiani  3 , Giampiero Girolomoni  13 , Claudio Guarneri  14 , Claudia Lasagni  15 , Francesco Loconsole  16 , Angelo Valerio Marzano  8   17 , Matteo Megna  12 , Francesca Sampogna  18 , Massimo Travaglini  19 , Antonio Costanzo  1   2 , Alessandra Narcisi  1
Affiliations

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis)

Luigi Gargiulo et al. Front Med (Lausanne). .

Abstract

Introduction: Brodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family. It has been approved for the treatment of moderate-to-severe plaque psoriasis after being evaluated in three Phase-3 trials. However, long-term data on brodalumab in a real-life setting are still limited.

Methods: The aim of this study was to evaluate the long-term effectiveness and safety of brodalumab in psoriasis. We also assessed the drug survival of brodalumab in a 3 years timespan. We conducted a retrospective multicenter study on 606 patients followed up at 14 Italian dermatology units, all treated with brodalumab according to Italian guidelines. Patients' demographics and disease characteristics were retrieved from electronic databases. At baseline and weeks 12, 24, 52, 104 and 156, we evaluated the psoriasis area and severity index (PASI) score and investigated for adverse events. The proportions of patients reaching 75, 90 and 100% (PASI 75, PASI 90 and PASI 100, respectively) improvement in PASI, compared with baseline, were also recorded.

Results: At week 12, 63.53% of the patients reached PASI 90 and 49.17% PASI 100. After 3 years of treatment, 65.22% of patients maintained a complete skin clearance, and 91.30% had an absolute PASI of 2 or less. Patients naïve to biological therapies had better clinical responses at weeks 12, 24 and 52. However, after 2 years of treatment, no significant differences were observed. Body mass index did not interfere with the effectiveness of brodalumab throughout the study. No new safety findings were recorded. After 36 months, 85.64% of our patients were still on treatment with brodalumab.

Conclusion: Our data confirm the effectiveness and the safety of brodalumab in the largest real-life cohort to date, up to 156 weeks.

Keywords: brodalumab; psoriasis; psoriasis treatment; psoriatic arthritis; real-life.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Clinical effectiveness of brodalumab throughout 156 weeks. PASI, psoriasis area and severity index; mPASI: mean PASI.
Figure 2
Figure 2
Effectiveness of brodalumab according to previous exposure to biological therapies. PASI, psoriasis area and severity index; mPASI: mean PASI. *p-value <0.05; **p-value ≤0.01; ***p-value ≤0.001.
Figure 3
Figure 3
Kaplan–Meier curve of all-cause treatment discontinuation in all patients treated with brodalumab up to 36 months.
See this image and copyright information in PMC

References

    1. Dave R, Alkeswani A. An overview of biologics for psoriasis. J Drugs Dermatol. (2021) 20:1246–7. doi: 10.36849/jdd.6040 - DOI - PubMed
    1. Boehncke WH, Brembilla NC. Pathogenesis-oriented therapy of psoriasis using biologics. Expert Opin Biol Ther. (2022) 22:1463–73. doi: 10.1080/14712598.2022.2100219 - DOI - PubMed
    1. Narcisi A, Valenti M, Gargiulo L, Ibba L, Amoruso F, Argenziano G, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52 weeks multicentre retrospective study-IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. (2023) 37:93–103. doi: 10.1111/jdv.18594, PMID: - DOI - PMC - PubMed
    1. Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S. The TNF/IL-23/IL-17 axis-head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. (2020) 92:e12946. doi: 10.1111/sji.12946, PMID: - DOI - PubMed
    1. Gargiulo L, Ibba L, Malagoli P, Angileri RG, Bardazzi F, Bernardini N, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104 weeks multicenter retrospective study—IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. (2023) 37:1017–27. doi: 10.1111/jdv.18913, PMID: - DOI - PubMed